CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease.
Lizama BN, Williams C, North HA, Pandey K, Duong D, Di Caro V, Mecca AP, Blennow K, Zetterberg H, Levey AI, Grundman M, van Dyck CH, Caggiano AO, Seyfried NT, Hamby ME.
Lizama BN, et al. Among authors: blennow k.
Alzheimers Dement. 2024 Oct;20(10):6860-6880. doi: 10.1002/alz.14152. Epub 2024 Aug 21.
Alzheimers Dement. 2024.
PMID: 39166791
Free PMC article.
Clinical Trial.